netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Introduction

Preferred Prescribing list for South Staffordshire CCGs, including Burton Hospital NHS Foundation Trust and
Cannock and Stafford Hospitals Foundation Trust

Useful Links

BNFSPC  Area Prescribing Group Minutes CCG Patient Group Directions and Patient Specific Directions Prescribing Commissioning and over the counter
Policies
Feedback To Us Link
BNF For Children New Medicines Committee Documents CCG Newsletters NHS England Patient Group Directions    High Cost Drugs
MHRA Drug Safety Updates Decline To Prescribe Form Vaccine Update Prescribing Audits  Communications and drug discontinuations
Care Home Prescribing Resourses Cross Border prescribing guideline     

Covid-19 

Interim Clinical Information 

RICaDs and ESCAs
Burton Hospital NHS Trust
Essential Shared Care Agreements
RICaDs MPFT Mental Health Essential Shared Care Agreements
Clinical Formularies and Guidelines
Area Prescribing Group Guidelines Woundcare Formulary Antimicrobial Guidance Continence Prescribing Formulary
CCG Formularies
North Staffs Joint Formulary Birmingham and Surrounds Formulary Derbyshire Formulary  Wolverhampton Formulary

 

News Feed

07/05/2020 - New Covid-19 information link

The South Staffordshire Joint Formulary has a new COVID 19 link titled Interim Clinical Information. Please use this link to access local and national documents recommending advice and guidance during this time. If you have any queries relating to this please use the Feedback tab on the formulary front page.

Medicines Information Team


19/03/20 Esmya: Urgent patient level recall

Gedeon Richter (UK) Ltd is recalling all unexpired stock of Ulipristal acetate (Esmya) from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine. To protect patients while a safety review is conducted, the European Medicines Agency's safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.

Clinicians must contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should be provided advice about other possible treatments for uterine fibroids.  


24/02/20: Three Insuman preparations to be discontinued.

Three presentations of Insuman Basal and Insuman Comb are to be discontinued owing to limited capacity at the manufacturing site. The manufacturer says the discontinuations are not due to any safety issue.

The presentations being discontinued are:

  • Insuman Comb 15 100IU/mL suspension for injection in a cartridge (expected end of supply June 2020). This is the only presentation of Insuman Comb 15.
  • Insuman Basal 100IU/mL suspension for injection in a vial (expected end of supply May 2020).
  • Insuman Comb 25 100IU/mL suspension for injection in a vial (expected end of supply June 2020).

No new patients should be started on these presentations, and existing patients should be switched to a suitable alternative. See individual entries on the formulary for alternatives.


21/11/19: Asthma guidelines for Staffordshire and SOT CCGs

The APC/APG has approved the Staffordshire and SOT CCGs Asthma Guidelines. This document is now available on netFormulary. Clinicians should familiarise themselves with the document and employ its use in clinical practice. Any queries can be directed to the Medicines Optimisation Team. 


14/10/19: Update on current supply issue of all brands of adrenaline auto-injectors

Clinicians should note the latest stock availability update from DHSC concerning adrenaline auto-injectors (see table below). Due to the supply issues with some brands, it may be necessary to switch patients to an alternative brand that they are unfamiliar with. Clinicians should support switching and ensure patients know how to use the alternative product that is supplied. 

Adrenaline auto-injector brand
Strength
MA Holder
Stock Availability
EpiPen Junior
150 micrograms
Mylan UK
Available under prescription validation
EpiPen
300 micrograms
Mylan UK
Available under prescription validation
Jext
150 micrograms
ALK-Abello
Available
Jext
300 micrograms
ALK-Abello
Available from w/c 14th October
Emerade
150 micrograms
Bausch & Lomb
Available
Emerade
300 micrograms
Bausch & Lomb
Available from w/c 14th October
Emerade
500 micrograms
Bausch & Lomb
Available from 18th October

Specific training and advice are required for each of the devices. Please follow the links to the relevant training videos below:

EpiPen:            http://www.epipen.co.uk/demonstrationvideo/

Jext:                 https://hcp.jext.co.uk/

Emerade:          https://www.emerade-bausch.co.uk/patient/how-to-use-emerade


01/08/2019:  Emerade® adrenaline auto-injectors supply issues

There is a short-term supply issue affecting Emerade® 500 microgram and 300 microgram adrenaline auto-injectors (AAIs). Bausch & Lomb are the sole UK supplier of Emerade® devices in the UK. New supplies of Emerade® 500 microgram are expected by the end of August 2019. Limited stock of Emerade® 300 microgram is available. Currently, new supplies are expected by the end of September 2019.

Two alternative AAI devices are available in the UK- EpiPen® and Jext®. Both Jext® and EpiPen® AAIs are currently available, however, supplies of Jext® are unlikely to be sufficient to support a significant switch to this product and therefore where there is no patient / clinician preference, EpiPen® should be considered as the first line alternative. The devices differ slightly in the administration technique and specific training is required for each device.


>>> more news

HOW TO USE

  1. The Preferred Prescribing List for the various therapeutic sections of  the British National Formulary (BNF) can be accessed via the links

   2.     PDF How to use guide

   3.   Drugs are colour coded according to the following criteria:

 

Status Description
Red Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  
Amber Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  
Amber E Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)
Green Suitable first-line drugs for implementation in Primary Care  
Green Formulary South Staffs Formulary Choice

 


NetFormulary
   Visits = 350309
   Last updated: 26/06/2020 14:15:26..